These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6377392)

  • 21. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].
    Ol'binskaia LI; Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
    Ter Arkh; 1991; 63(8):61-4. PubMed ID: 1792621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of fenofibrate on apolipoprotein B containing lipoprotein particles.
    Fruchart JC; Bard JM; Fievet C; Kandoussi A; Slimane M; Douste-Blazy P
    Prog Clin Biol Res; 1988; 255():305-10. PubMed ID: 3277201
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
    Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
    [No Abstract]   [Full Text] [Related]  

  • 27. Attempts with lipanthyl to improve lipid metabolism during the adaptation period of women taking oral contraceptives.
    Pilishegyi J
    Ther Hung; 1989; 37(4):225-9. PubMed ID: 2631290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 29. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of effect of a purified bran preparation in men with low HDL cholesterol.
    Lithell H; Selinus I; Vessby B
    Hum Nutr Clin Nutr; 1984 Jul; 38(4):309-13. PubMed ID: 6088439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of gemfibrozil on serum lipid levels.
    Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
    Artery; 1980; 7(3):224-31. PubMed ID: 7008748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum lipoprotein pattern after SAMe-treatment.
    Rini GB; Di Fede G; Rotolo G; Rizzo G; Mascellino MR; Affronti M; Delle Vedove G
    Boll Soc Ital Biol Sper; 1987 Oct; 63(10):919-22. PubMed ID: 3447603
    [No Abstract]   [Full Text] [Related]  

  • 35. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of procetofen on the lipoprotein profile in patients with type II hyperlipoproteinemia].
    Drouin P; Méjean L; Lambert D; Sauvanet JP; Debry G
    Med Welt; 1979 Dec; 30(50):1910-3. PubMed ID: 548697
    [No Abstract]   [Full Text] [Related]  

  • 37. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D; Petrova V; Belovezhdov N
    Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
    Reiner Z; Salzer B; Kes P
    Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.